In this exclusive interview Jesús Zurdo, Head of Innovation, Biopharma Development, Lonza Biologics, speaks to Andrea Charles from Pharma IQ about improving the developability of biopharmaceuticals, the advantages of implementing early risk assessment and enhancing manufacture through Quality By Design (QbD). Zurdo also shares his views on the future and true promise of QbD.
Pharma IQ: What sort of current trends have you witnessed, with regards to improving the developability of bio...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More